Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11537623 | 0.70 | SLC6A9 (0.34) | GAA | |
| SCHEMBL11537617 | 0.70 | SLC6A9 (0.34) | GAA | |
| SCHEMBL11065703 | 0.70 | SMN1; SMN2 (0.34) | FFAR3CA12CA9 | |
| SCHEMBL11537621 | 0.70 | SLC6A9 (0.34) | GAA | |
| SCHEMBL22128614 | 0.70 | HTR2C (0.39) | FUCA1 | |
| Hydrochloric Acid SCHEMBL26914386 | 0.69 | HTR2C (0.38) | FUCA1 | |
| SCHEMBL941940 | 0.68 | MGAM (0.42) | FUCA1GAA | |
| SCHEMBL20225057 | 0.68 | MGAM (0.42) | FUCA1GAA | |
| SCHEMBL17756759 | 0.67 | RECQL (0.41) | — | |
| SCHEMBL13248935 | 0.67 | RECQL (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | VIDA PHARMA LIMITED (GB) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10842784-B2 | Treatment of energy utilization disease | IRS1, SLC2A1, INSR | FUCA1 1506/4885GAA 268/4885FFAR3 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.